DigiCon

@if (isset(session()->get('doctor')['vCentralCode']))

Back

@else

@endif

A survey among Indian healthcare practitioners to understand In-Practice usage of mirabegron in management of Neurogenic Lower Urinary Tract Dysfunction

Survey Questionnaire Form

Doctor's details

Questionnaire

In your clinical practice, what is the average number of Neurogenic lower urinary tract dysfunction (NLUTD) you consult per month? *

<10%

10-20%

20-30%

30-40%

40-50%

>50%

What are the pharmacotherapy options for NLUTD you prescribe in your clinical practice? *

In your clinical practise, Is Mirabegron your first line option in the treatment of NLUTD? *

Yes

In what percentage of NLUTD patients do you currently prescribe mirabegron as add on to existing therapy? *

10-20%

20-30%

30-40%

40-50%

>50%

In your clinical practice, what is the dosage of Mirabegron you prefer in NLUTD? *

25 mg once a day

50 mg once a day

What is the duration of Mirabegron treatment for NLUTD patients in your clinical practice? *

15 days

15 days-30 days

Between 30-60 days

More than 60 days

In what percentage of NLUTD patients do you prefer Anticholinergics as initial therapy? *

10-20%

20-30%

30-40%

40-50%

>50%

In your clinical practise, which is the preferred Anticholinergic in NLUTD? *

Molecule	Preference (Y/N)	Strength	Dosage
Solifenacin	Yes No
Darifenacin	Yes No
Tolterodine	Yes No
Oxybutynin	Yes No
Fesoterodine	Yes No

In your clinical practise, how you rank mirabegron in terms of efficacy, safety & tolerability for treating NLUTD?*
(1- Poor, 2 –Neutral, 3 – Good)

Attributes	Mirabegron as Add on in NLUTD	Mirabegron as initial in NLUTD
Efficacy
Safety and tolerability

In which of the following symptoms have you observed significant reduction in episodes, on treatment with Mirabegron, in patients of NLUTD (Please tick) *

	Urgency	Frequency	Incontinence	Nocturia
Mirabegron

In your clinical practice, how do you rank antimuscarinic rank in terms of efficacy, safety & tolerability for treating NLUTD? *
(1- Poor, 2 –Neutral, 3 – Good)

Attributes	Antimuscarinic as add on in NLUTD	Antimuscarinic as initial therapy in (NLUTD)
Efficacy
Safety and tolerability

In which of the following symptoms have you observed significant reduction in episodes on treatment with antimuscarinics in NLUTD (Please tick) *

	Urgency	Frequency	Incontinence	Nocturia
Antimuscarinic

In your clinical practise, what are the typical urodynamic parameters that show improvement in neurogenic bladder patients treated with Mirabegron? *

In your opinions, are there any specific subgroups of neurogenic bladder patients that may benefit with Mirabegron treatment? *

In your clinical practice, do you also explore combination therapies involving Mirabegron with other pharmacological agents for enhanced efficacy in NLUTD? If yes, please mention your preferred combinations? *

Yes

In your clinical practice, what % of patients are paediatric patients out of total patients of NLUTD consulted by you in a month? *

<10%

10-20%

20-30%

30-40%

40-50%

>50%

In your clinical practice, what are the current pharmacotherapy options you prescribe for pediatric NLUTD patients? *

Which are the factors do you consider for using mirabegron as monotherapy or as an add-on to other treatments (e.g., antimuscarinics or botulinum toxin injections)? *

In your clinical practice, how do you rank antimuscarinic rank in terms of efficacy, safety & tolerability for treating pediatric NLUTD? *
(1- Poor, 2 –Neutral, 3 – Good)

Attributes	Antimuscarinic as add on in NLUTD	Antimuscarinic as initial therapy in (NLUTD)
Efficacy
Safety and tolerability

What challenges or limitations have you encountered with current treatment option available for NLUTD?*